VALD-3 Triggers Pyroptosis in Triple-Negative Breast Cancer Through ROS/JNK/Bax Pathway

A synthetic compound derived from a family of molecules first described in the nineteenth century is emerging as a surprising weapon against one of the most stubborn forms of breast cancer. In a study published in the journal Biochemical Genetics, researchers in China report that VALD-3, a Schiff base ligand derivative synthesized from o-vanillin, kills triple-negative breast cancer cells through an unusual and inflammatory form of cell death known as pyroptosis. The findings reveal a detailed molecular pathway that could point toward new therapeutic strategies for a disease that currently has the poorest prognosis of all breast cancer subtypes.

Triple-negative breast cancer, or TNBC, accounts for a disproportionate share of breast cancer deaths worldwide. Unlike other breast cancers, TNBC cells lack estrogen receptors, progesterone receptors, and excess HER2 protein, the three molecular targets that drive most modern breast cancer therapies. That absence means patients cannot benefit from hormone therapy or HER2-directed drugs, leaving chemotherapy as the main systemic option. The result is high malignancy, an elevated risk of recurrence and metastasis, and limited therapeutic choices. Against this backdrop, the search for compounds that can eliminate TNBC cells through novel mechanisms has become a pressing priority in oncology research.

The compound at the center of the new study belongs to the Schiff base family, a class of organic molecules formed through a condensation reaction first characterized by Hugo Schiff in 1864. Schiff bases contain an imine functional group, a carbon-nitrogen double bond, and have long been prized in medicinal chemistry for their structural versatility and biological activity. VALD-3 itself is a derivative synthesized from o-vanillin, and it is not entirely new to cancer researchers. Earlier work showed that VALD-3 can induce cell cycle arrest and apoptosis in breast cancer cells by inhibiting the Wnt/β-catenin pathway, and separate studies found it suppresses colorectal cancer cells by upregulating the tumor suppressor p53. The new research, however, uncovers a far more dramatic mode of action.

When the research team, led by Xuhui Zhao of Gansu Provincial Hospital in Lanzhou and including collaborators from Northwest Normal University, exposed breast cancer cells to VALD-3 in the laboratory, they observed cytotoxic effects on both TNBC cells and estrogen receptor-positive MCF-7 cells. Crucially, however, the compound was significantly more potent against the triple-negative cells. And the way those cells died was anything but ordinary. Under the microscope, the cells displayed the unmistakable hallmarks of pyroptosis: they swelled dramatically, sprouted balloon-like protrusions from their membranes, and eventually burst, releasing a flood of inflammatory cytokines into their surroundings.

Pyroptosis is a relatively recent addition to the catalog of programmed cell death. Long familiar as apoptosis, the quiet, orderly suicide of cells, biologists have increasingly recognized that cells can also die in a much louder fashion. First described in immune cells infected by bacteria, pyroptosis is a form of inflammatory programmed cell death in which pores form in the plasma membrane, causing the cell to swell, rupture, and spill its pro-inflammatory contents. The gasdermin family of proteins provides the execution machinery. When a gasdermin protein is cleaved, its pore-forming domain is unleashed, punching holes in the cell membrane. One member of this family, gasdermin E, or GSDME, has attracted particular attention because it can convert the apoptotic program into pyroptosis: caspase-3, the central executioner of apoptosis, can cleave GSDME, transforming a silent death into an explosive one. Intriguingly, GSDME has also been shown to suppress tumor growth by activating anti-tumor immunity, which makes inducing GSDME-dependent pyroptosis an attractive strategy in cancer therapy.

The mechanistic detective work in the new study traced a clear signaling cascade from the initial drug exposure to the final rupture of the cell membrane. The first domino to fall was reactive oxygen species, or ROS. VALD-3 treatment caused ROS levels inside TNBC cells to climb. Far from being mere metabolic noise, ROS at high levels act as potent signaling molecules, particularly within the mitochondria, the energy-producing organelles that are also central arbiters of cell death decisions. Excessive mitochondrial ROS is a well-established trigger of apoptotic signaling, and many anticancer agents exploit precisely this vulnerability.

The rising ROS levels in turn drove the phosphorylation of JNK, a stress-activated protein kinase that relays oxidative stress signals to the mitochondrial machinery. Activated JNK promoted the recruitment of Bax, a pro-apoptotic member of the Bcl-2 protein family, to the outer mitochondrial membrane. There, Bax formed a heterodimer with Bcl-2, the family’s signature anti-apoptotic protein, effectively neutralizing the cell’s principal defense against self-destruction. With Bax entrenched on the mitochondria and Bcl-2 sequestered, the outer mitochondrial membrane became permeable, and cytochrome c, a protein normally tucked away in the space between the mitochondrial membranes, spilled into the cytoplasm. This release is the classic point of no return in the intrinsic apoptotic pathway.

Once in the cytoplasm, cytochrome c set in motion the activation of caspase-3, the protease that dismantles the cell from within. But here the story took its decisive turn. Instead of ending quietly in apoptosis, the activated caspase-3 cleaved gasdermin E. The cleaved GSDME fragments migrated to the plasma membrane and began forming pores, producing the swelling, ballooning, and inflammatory rupture that the researchers had observed. In other words, VALD-3 hijacked the standard apoptotic machinery and diverted it into pyroptosis, initiating the ROS/JNK/Bax-mitochondrial apoptosis pathway and culminating in caspase-3 activation and GSDME cleavage. The result was the complete eradication of the cancer cells through a mechanism that simultaneously recruits the immune system to the tumor site.

Perhaps the most clinically tantalizing observation is the selectivity of this process. Although VALD-3 was toxic to both TNBC and ER-positive MCF-7 cells, the characteristic pyroptotic features emerged selectively in the triple-negative cells. This preferential induction of pyroptosis in the harder-to-treat subtype suggests that TNBC cells may be especially vulnerable to this form of death, or that their GSDME expression and mitochondrial stress responses make them uniquely susceptible to the ROS-driven cascade. Either way, the specificity offers a potential therapeutic window: a treatment that devastates TNBC cells while sparing mechanisms that might fuel inflammation-driven progression in other tumor contexts.

The study is not the first to connect ROS-driven stress to GSDME-dependent pyroptosis in TNBC. Tetraarsenic hexoxide, for example, has been reported to promote pyroptosis in these cells through mitochondrial ROS generation and caspase-3/GSDME activation, and triclabendazole, a veterinary anthelmintic, has been shown to activate the same caspase-3/GSDME axis in breast cancer cells. What distinguishes the new work is both the identity of the agent, a rationally designed Schiff base derivative with a growing portfolio of anticancer activity, and the completeness of the pathway map, which connects ROS production through JNK phosphorylation, Bax mitochondrial recruitment, Bcl-2 sequestration, cytochrome c release, and caspase-3 activation all the way to GSDME cleavage and membrane rupture.

The researchers, based at Gansu Provincial Hospital, The First People’s Hospital of Longxi County, and Northwest Normal University, also tested the compound’s effects on tumor growth in vivo, reporting that VALD-3 treatment inhibited tumor growth, consistent with the pyroptotic cell death observed in culture. The work was funded by the Natural Science Foundation of China and several Gansu provincial research programs, reflecting a concerted effort to develop locally synthesized chemical entities into credible anticancer candidates.

There are, of course, substantial hurdles between a laboratory observation and a clinical therapy. Pyroptosis is a double-edged sword: the inflammatory cytokines released by dying cells can stimulate anti-tumor immunity, but excessive inflammation can also cause tissue damage and, in some contexts, promote tumor progression. Researchers will need to establish careful dosing strategies, verify the selectivity in normal tissues, and determine whether GSDME expression levels in patient tumors can serve as a biomarker to identify who would benefit most from such treatment. The safety profile of VALD-3 in humans remains entirely untested.

Even so, the study adds a compelling entry to the expanding repertoire of pyroptosis-inducing anticancer strategies and offers a new mechanistic explanation for the activity of a compound that researchers have been probing for years. For patients with triple-negative breast cancer, whose options remain constrained by the biology of their disease, the prospect of a small molecule that converts the cancer cell’s own death machinery into an immune-activating fire alarm is a reason for cautious optimism. The findings suggest that GSDME-dependent pyroptosis is a novel mechanism by which VALD-3 eradicates cancer cells, and they offer new insights into potential clinical applications for anticancer therapies aimed at the most aggressive form of breast cancer.